AdvaMed Statement on Vice President Biden's National Cancer Moonshot Summit
Wednesday, June 29, 2016
Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed) and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement in support of Vice President Biden’s National Cancer Moonshot Summit:
“The Cancer Moonshot Summit taking place today is a step forward in breaking down barriers to progress, enhancing research, and ultimately eliminating cancer as we know it, and we commend Vice President Biden and Greg Simon, director of the Moonshot Initiative, on their important work. We also extend our appreciation for the opportunity offered by the Vice President and his team for representatives of AdvaMed member companies to participate in the Summit.
"In terms of cancer treatment and care, our member companies produce products and technologies that support people living with cancer and their health care providers through oncology research, diagnosis, radiotherapy treatments, surgery, and follow up care. Diagnostic testsand imaging technologies provide vital information that guides cancer diagnosis and treatment, while radiotherapies and surgical oncology tools provide life-saving cancer effective treatment and improve outcomes for people with cancer.
“As a whole, AdvaMed member companies are leading innovators of a formidable array of technologies that are cornerstones of the modern health care system and revolutionizing cancer care.
“We urge the Taskforce and policymakers to fully leverage the contributions of the medical technology industry and welcome the opportunity to work together to further highlight medical technologies’ numerous contributions. We are encouraged by the broad level of support for initiatives like Precision Medicine and 21st Century Cures, both of which are policies that, if implemented, would substantially improve access to cutting edge, life-saving technologies.”